PCM
Penserra Capital Management Portfolio holdings
AUM
$7.17B
1-Year Return
49.58%
This Quarter Return
+33.7%
1 Year Return
+49.58%
3 Year Return
+118.16%
5 Year Return
+229.83%
10 Year Return
–
AUM
$4.23B
AUM Growth
+$1.6B
(+61%)
Cap. Flow
+$935M
Cap. Flow
% of AUM
22.08%
Top 10 Holdings %
Top 10 Hldgs %
21.32%
Holding
1,174
New
230
Increased
606
Reduced
167
Closed
168
Top Buys
| 1 |
KE Holdings
BEKE
|
+$78.6M |
| 2 |
Lufax Holding
LU
|
+$56.6M |
| 3 |
Groupon
GRPN
|
+$50.3M |
| 4 |
JD.com
JD
|
+$43.7M |
| 5 |
Lands' End
LE
|
+$36.7M |
Top Sells
| 1 |
JMIA
Jumia Technologies
JMIA
|
+$35.9M |
| 2 |
Peloton Interactive
PTON
|
+$31.3M |
| 3 |
Match Group
MTCH
|
+$23.5M |
| 4 |
Fiverr
FVRR
|
+$16.6M |
| 5 |
Stitch Fix
SFIX
|
+$14.7M |
Sector Composition
| 1 | Consumer Discretionary | 35.59% |
| 2 | Technology | 23.48% |
| 3 | Communication Services | 13.86% |
| 4 | Real Estate | 4.37% |
| 5 | Industrials | 4.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
801
Repare Therapeutics
RPTX
$75.2M
| $28K | ﹤0.01% |
+845
| New | +$28K |
|
|
IMGN
802
DELISTED
Immunogen Inc
IMGN
| $28K | ﹤0.01% |
4,370
+2,880
| +193% | +$18.5K |
|
|
BKI
803
DELISTED
Black Knight, Inc. Common Stock
BKI
| $28K | ﹤0.01% |
320
-914
| -74% | -$80K |
|
|
AVLR
804
DELISTED
Avalara, Inc.
AVLR
| $28K | ﹤0.01% |
+170
| New | +$28K |
|
805
Alector
ALEC
$284M
| $27K | ﹤0.01% |
1,840
+1,164
| +172% | +$17.1K |
|
|
ITOS
806
DELISTED
iTeos Therapeutics
ITOS
| $27K | ﹤0.01% |
+805
| New | +$27K |
|
807
Korro Bio
KRRO
$330M
| $27K | ﹤0.01% |
+16
| New | +$27K |
|
808
Krystal Biotech
KRYS
$3.98B
| $27K | ﹤0.01% |
+450
| New | +$27K |
|
809
Packaging Corp of America
PKG
$19.2B
| $27K | ﹤0.01% |
197
+61
| +45% | +$8.36K |
|
810
Wabtec
WAB
$32.4B
| $27K | ﹤0.01% |
379
+107
| +39% | +$7.62K |
|
811
Karyopharm Therapeutics
KPTI
$55.5M
| $26K | ﹤0.01% |
113
+71
| +169% | +$16.3K |
|
812
Molina Healthcare
MOH
$9.68B
| $26K | ﹤0.01% |
126
+58
| +85% | +$12K |
|
813
Passage Bio
PASG
$22.5M
| $26K | ﹤0.01% |
+52
| New | +$26K |
|
814
Theravance Biopharma
TBPH
$686M
| $26K | ﹤0.01% |
1,465
+923
| +170% | +$16.4K |
|
815
Altice USA
ATUS
$1.08B
| $26K | ﹤0.01% |
709
+165
| +30% | +$6.05K |
|
816
Black Diamond Therapeutics
BDTX
$183M
| $26K | ﹤0.01% |
+825
| New | +$26K |
|
817
C.H. Robinson
CHRW
$15B
| $26K | ﹤0.01% |
283
+79
| +39% | +$7.26K |
|
818
Factset
FDS
$13.7B
| $25K | ﹤0.01% |
78
+10
| +15% | +$3.21K |
|
819
Gen Digital
GEN
$18.1B
| $25K | ﹤0.01% |
1,219
+267
| +28% | +$5.48K |
|
820
Jack Henry & Associates
JKHY
$11.6B
| $25K | ﹤0.01% |
159
+57
| +56% | +$8.96K |
|
821
W.P. Carey
WPC
$14.8B
| $25K | ﹤0.01% |
372
+94
| +34% | +$6.32K |
|
|
EPZM
822
DELISTED
Epizyme, Inc
EPZM
| $25K | ﹤0.01% |
2,330
+1,464
| +169% | +$15.7K |
|
|
ZGNX
823
DELISTED
Zogenix, Inc.
ZGNX
| $25K | ﹤0.01% |
1,275
+801
| +169% | +$15.7K |
|
824
Adverum Biotechnologies
ADVM
$69M
| $24K | ﹤0.01% |
224
+143
| +177% | +$15.3K |
|
825
Arcturus Therapeutics
ARCT
$477M
| $24K | ﹤0.01% |
+560
| New | +$24K |
|